Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway

on

Psyence BioMed (Nasdaq:
PBM) board ratified a Put Option Agreement with PsyLabs on February 13, 2026.12

The agreement grants PsyLabs the right to require Psyence BioMed to make a future share-for-share equity investment at fair market value, preserving near-term cash.123

It secures long-term access to GMP-compliant pharmaceutical-grade psilocybin and ibogaine supply for clinical and commercial programs.14

A Special Committee of independent directors and independent third-party valuation were used due to executives' consulting roles and <13% ownership in PsyLabs.12

The deal is part of a broader strategic relationship including licensing for PsyLabs' manufacturing capabilities, de-risking supply chain.14

Stock surged 9.96% following the announcement, viewed as a positive step in the $8.75B psychedelic market.4

Sources:

1. https://www.stocktitan.net/news/PBM/psyence-bio-med-approves-put-option-agreement-with-psy-labs-to-bouah210f3s3.html

2. https://www.stocktitan.net/sec-filings/PBM/6-k-psyence-biomedical-ltd-current-report-foreign-issuer-fcea2ff95d93.html

3. https://psyencebiomed.com/put-option-agreement-with-psylabs/

4. https://www.ainvest.com/news/psyence-biomed-put-option-deal-assessing-scalability-bet-8-75b-psychedelic-market-2602/